-
Draft guidelines by the Centers for Disease Control and Prevention ratchet up increasing infection control and administrative measures depending on whether severe acute respiratory syndrome (SARS) has appeared globally, within a community, or within a facility.
-
Editors note: As this issue of Hospital Infection Control went to press, these studies were presented in Chicago at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Look for more in-depth coverage of this conference in our next issue
-
There is an increasing emphasis in infection control on doing active surveillance cultures and detecting and isolating patients colonized with pathogens such as vancomycin-resistant enterococci (VRE).
-
Diverging from the position taken by the Geneva-based World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC) will not urge influenza vaccination for the 2003-2004 season specifically as a response to the possible return of severe acute respiratory syndrome (SARS), Hospital Infection Control has learned.
-
Draft guidance by public health officials preparing for a seasonal resurgence of severe acute respiratory syndrome (SARS) calls for taking the controversial step of masking all incoming patients with respiratory symptoms, Hospital Infection Control has learned.
-
Updated EMTALA rule eases hospitals risk; Johns Hopkins program loses its accreditation; AMA to provide ethics alerts to MDs
-
The privacy regulations enacted as part of the federal Health Insurance Portability and Accountability Act (HIPAA) have caused some unforeseen complications for hospitals trying to ensure patient safety and improve communication between providers and patients, say health care professionals and legal experts.
-
Would your ethics committee approve a request to perform nontherapeutic surgery that would permanently alter the body of a healthy patient without his or her consent? What if the patient was very young and the parents wanted the surgery for religious or cultural reasons?
-
For cancer patients who have exhausted all available treatment options, Phase I research trials of new oncology drugs may be their only hope. But does that hope come at too high a price?
-